Staff

Last Chance for Children is Proud to Announce its Partnership with Generex Biotechnology & NuGenerex Immuno-Oncology to SAFELY and EFFECTIVELY Vaccinate Children and Pregnant Women

Context Therapeutics and Integral Molecular Enter Collaboration and License Deal for Novel Claudin 6 Antibodies for Gynecologic Cancer Therapeutic Program

PHILADELPHIA, April 08, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics, a clinical-stage women’s oncology company developing advanced small molecule and immunotherapy...

error: Content is protected !!